Inclusion Criteria:  Subject age greater than or equal to 18 years at the time of signature of informed consent. Subjects with an incurable malignancy who have been identified to have a rare cancer or rare molecular aberration who is currently receiving Health Canada approved targeted therapy that is not nationally funded ECOG 0-2 Life expectancy of at least 12 weeks Adequate hematologic and end organ function for drug treatment per the clinician's assessment Asymptomatic or treated brain metastases permitted Ability to give informed consent for the study procedures defined in this protocol.  Exclusion Criteria:  Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days prior to enrollment. Inability to complete quality of life questionnaires Subjects who are felt by the treating clinician to be unfit to proceed with this protocol.